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Abstract 
Ergothioneine, a natural thiol-containing molecule, has recently been proposed to protect the heart against damage caused by 
ischaemia nd reperfusion. We investigated the possibility that ergothioneine can have a role in maintaining the myocardial thiol/dis- 
ulfide balance and consequently also a protective ffect against ischaemic and reperfusion i jury. We used isolated Langendorff-perfused 
rabbit hearts subjected to 45 rain global and total ischaemia followed by 30 min reperfusion at baseline coronary flow (22 ml/min). 
Ergothioneine was delivered at 10 -5 M and 10 -4 M 60 rain before ischaemia nd during reperfusion. Myocardial damage was 
determined in terms of mechanical function, creatine kinase (CK) and lactate release, energy phosphate stores and the occurrence of 
oxidative stress. In our experimental conditions the treatment was unable to prevent myocardial damage. Ergothioneine, independently 
from the dosage used, failed to: (i) increase recovery of developed pressure upon reperfusion (14.4 + 2.3 mmHg in control hearts vs. 
10.3 + 2.9 and 12.5 + 2.3 mmHg in 10 -5 M and 10 -4 M ergothioneine treated hearts, respectively); (ii) decrease the rise in diastolic 
pressure (44.3 + 4.4 mmHg in control hearts vs. 49.8 + 5.8 and 48.0 -/- 7.7 mmHg in treated hearts); (iii) decrease the release of CK and 
lactate; (iv) increase the levels of adenosine triphosphate (ATP) and creatine phosphate (CP) in tissue upon reperfusion; (v) maintain ratio 
between oxidized and reduced forms of adenine nucleotide coenzyme, as index of aerobic metabolism; (vi) prevent he decline of reduced 
glutathione (GSH), or the accumulation of oxidized glutathione (GSSG) as an index of oxidative stress. 
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1. Introduction 
Ergothioneine is a thiol-histidine synthesized by lower 
eukaryots ( Neurospora crassa and Claviceps purpurea); it
represents the main component of the thiol pool [1,2]. In 
mammals, where ergothioneine is present in soluble frac- 
tion and reaches high concentrations (mM) in erythrocytes, 
seminal fluid, liver and kidney [1,3-6], the source of 
ergothioneine is from the dietary intake [1,3-7]. 
The physiological role of this thiolic compound has not 
been completely explained; nevertheless, there exist sev- 
eral hypotheses [8] regarding it. Recently, a generic antiox- 
idant activity in mammalian tissue has been proposed for 
ergothioneine [2]. This metabolic role was suggested on 
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the basis of some experimental observations which pre- 
sented ergothioneine as protective against H202,  several 
radical species and some toxic electrophilic organic 
molecules [9-14]. It was demonstrated that ergothioneine 
prevents oxidation of myocardial myoglobin by H20 2 and 
protects the isolated rat heart from damage caused by 
oxygen-free radicals during reperfusion following is- 
chaemia. This finding, published by Arduini et al. [14], is 
relative to a significant reduction of lactate dehydrogenase 
(LDH) leakage in an ergothioneine treated group measured 
in perfusate collected uring the reperfusion of isolated rat 
hearts subjected to 15 min of global and total ischaemia. 
Our study aimed at evaluating the ergothioneine protec- 
tive effect against myocardial ischaemic and repeffusion 
injury. 
Given the presence of a thiol group in its molecule, we 
propose ergothioneine as a biological reductant. The hy- 
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pothesis that it could participate in the regulation of the 
thiol/disulfide xchange underlies the key role that cellu- 
lar thiols have in maintaining the redox status of cellular 
proteins through the reduction of protein disulfides and the 
quenching of oxidants [15,16]. Thus, the lowering of such 
a thiol concentration by oxygen-free radicals, as occurs 
during reperfusion, can lead to serious disturbances in the 
cellular egulatory system. 
Furthermore, the minimal metabolism to which ergoth- 
ioneine in mammalian tissues is subjected after ingestion 
seems significant [5]. Is it possible that ergothioneine 
represents a storage thiolic pool, i.e., a sort of reductant 
equivalents accumulation that the cell could utilize under 
oxidative stress conditions? 
In this study, we systematically evaluate the possibility 
of ergothioneine working as a protective thiol donor in 
isolated Langendorff perfused rabbit hearts subjected to 
global and total ischaemia followed by reperfusion. We 
monitored its effect on: (a) energetic metabolism easured 
in terms of anaerobic production of lactate, of high energy 
phosphates tissue contents (CP, adenosine triphosphate, 
ATP; adenosine diphosphate, ADP; and adenosine 
monophosphate, AMP) and of the ratio between oxidized 
and reduced forms of the adenine nucleotide coenzyme 
(NAD/NADH); (b) cellular damage measured in terms of 
CK leakage; (c) heart mechanical function measured as 
developed and diastolic pressure; and (d) cellular redox 
balance measured as occurrence of oxidative stress. 
checked by an Ellab thermometric probe (model CTD 85) 
in the pulmonary artery. They were paced using 
suprathreshold rectangular pulses at 0.1 ms duration at a 
rate of 180 beat/min. The stimuli were delivered via two 
platinum electrodes, one attached to the metal inflow 
cannula and the other to the ventricular apex. 
After a 30 min period of aerobic equilibration (22 
ml/min), the hearts were randomly divided into: aerobic 
hearts (n = 14) which were aerobically perfused for a 
further period of 135 min; the remaining hearts were made 
ischaemic after 60 min of aerobic perfusion by stopping 
the coronary flow for 45 min. Thereafter, coronary flow 
was re-established for 30 min. 
Ergothioneine was delivered at 10 -5 M (group 2, n = 4) 
and 10 -4  M (group 3, n = 5) before ischaemia (during the 
aerobic period of 60 min) and during reperfusion. The 
remaining hearts received saline vehicle (group 1, n -- 7). 
2.2. Left ventricular pressure measurements 
To obtain an isovolumetrically beating preparation, a 
fluid-filled balloon was inserted into the left ventricular 
cavity via the atrium. The balloon was connected by a 
fluid-filled polyethylene catheter to a Hewlett Packard 
transducer (model 1290 A OPT 002). At the beginning of 
the experiments, the amount of fluid in the balloon was 
adjusted to obtain a diastolic pressure of < 1.0 mmHg. 
2.3. Biochemical assays 
2. Materials and methods 
The reagents used were of analytical grade. The en- 
zymes used for the biochemical ssays were obtained from 
Sigma. Ergothioneine was from Serva Feinbiochemica. 
2.1. Heart perfusion 
Male, New Zealand white rabbits (2.0-2.3 kg), main- 
tained on a standard iet, were used. They were treated in 
compliance with the guidelines of the American Physio- 
logical Society. The animals were stunned by a blow to the 
head; the hearts were quickly removed and cooled in 
perfusion buffer (0°C). After being cleaned of connective 
tissue, the hearts (6.25 + 0.13 g, n = 26) were perfused 
using the Langendorff technique [17,18], with a modified 
Krebs-Henseleit buffer containing in mM: NaC1 115; 
NaHCO 3 25.0; KC1 4.0; KH2PO 4 0.9; MgSO 4 0.65; CaCI 2 
1.7 and D-glucose 11.0 [19,20]. The perfusion solution was 
heated to 37°C, bubbled with 95% 0 2 and 5% CO 2, and 
transported at a rate of 22 ml/min to the aortic cannula 
with a Gilson Minipuls 2 rotary pump. The hearts were 
jacketed (40-44°C) to provide a constant myocardial tem- 
perature of 37°C independent of coronary flow that was 
Analysis of coronary effluent 
Coronary effluent fractions were collected in cooled 
vials (0°C) at regular intervals during the entire period of 
reperfusion for CK and lactate determinations. 
CK activity was assayed spectrophotometrically by the 
method of Oliver [21]; lactate was measured enzymatically 
using the method of Hohorst et al. [22]. 
Tissue determinations 
At the end of the experiments, the hearts were clamped 
with precooled Wollenberger tongs and stored in liquid 
nitrogen. For the determination of GSH and GSSG, the 
tissue ( = 100 mg) was deproteinated with 3 M HC104 and 
the supernatant obtained after centrifugation at 6000 × g 
for 15 min was neutralized with 2 M KzCO 3. A sample of 
the neutralized extract was analyzed for total glutathione 
by the method of Tietze [23]. The reaction mixture (1.0 
ml) contained: 0.05 M potassium phosphate buffer (pH 
7.4), 1 mM EDTA, 0.1 mM 5,5'-dithiobis-(2 nitrobenzoic 
acid) (DTNB), 0.15 mM NADPH and an appropriate 
volume of sample. After 2 rain of preincubation, the 
reaction was initiated by the addition of 1 U of glutathione 
reductase and the rate of reduction of the DTNB was 
continuously monitored at 412 nm; the slope was propor- 
tional to the glutathione concentration ver the range of 0 
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to 1 /xM. GSSG was measured as described above after 
the preliminary reaction of GSH with 20 mM N-ethyl- 
maleimide followed by complete removal of unreacted 
sulfhydryl reagent with diethylether. 
To determine the content of tissue thiol groups, a 
portion of the left ventricle was homogenized as described 
by Sedlack and Lindsay [24] with 20 mM EDTA (pH 4.7), 
and filtered on nylon. Samples of homogenates were mixed 
with 0.2 M Tris-HCl (pH 8.2), 0.01 M DTNB and methanol 
to a final volume of 10 ml. A reagent blank (without 
sample) and a sample blank (without DTNB) were pre- 
pared in a similar manner. The mixture was incubated for 
30 rain at room temperature. 
The absorbance was read at 412 nm, and a molar 
extinction coefficient of 13 600 M- lcm-]  was used. 
The acid-soluble thiol group content (as an expression 
of non-protein sulfhydryl groups = NP-SH) was deter- 
mined similarly in the supernatant obtained after denatura- 
tion of the homogenate with ice-cold 50% trichloroacetic 
acid. 
Protein SH groups (P-SH) were determined by subtract- 
ing the acid-soluble from the total SH group content. 
Protein determination was carded out according to Brad- 
ford [25], using bovine serum albumin as standard. 
The extraction of energy phosphates (ATP and CP) and 
oxidized nicotinamide nucleotide (NAD) was carried out at 
-180°C in frozen tissue, both ground (mixed with 0.4 N 
HC104) and homogenized using an Ultra-Turrax. The ho- 
mogenate was centrifuged at 4000 X g for 10 min at 4°C, 
and the supernatant, adjusted to pH 6.0-6.5 with 6 N 
KOH, was used for analysis by high-performance liquid 
chromatography (Waters 600E multisolvent and a model 
990 photodiode array detector). Separations were per- 
formed on a Supelchem C18 3/.~m RP column (0.46 × 15 
cm) .  
The mobile phase consisted of a continuous gradient of 
acetonitrile (2.5-25% v /v )  in phosphate buffer from pH 
6.0 to pH 5.5. Detection was performed at 205 nm for CP 
and at 260 nm for ATP [26]. 
For the determination of reduced nicotinamide nu- 
cleotide (NADH), an alkaline extraction carried out with 
alcoholic potassium hydroxide solution (1 M) was used. 
pH was brought to 7.8 by slow addition of a 
threthanolamine/phosphate mixture [27]. The supernatant 
was utilized for the analysis following the same analytical 
conditions described for ATP, CP and NAD. 
2.4. Statistical analysis 
The data are reported as mean + S.E.M. A one-way 
analysis of variance was first carried out to test for any 
differences between all of the groups. If a difference was 
established, each group was compared with the control 
group (aerobic control) using Bonferroni's 't-test'. The 
results were considered to be significant if P < 0.05. 
3. Results 
Preliminary control studies confirmed the stability of 
the mechanical functions in rabbit hearts when aerobically 
perfused by the Langendorff technique for 150 min [20]. 
In control hearts, the abolition of coronary flow induced 
a rapid decline of the developed pressure. The diastolic 
pressure began to increase progressively after the onset of 
ischaemia nd by 45 min it had increased to 25.9 + 1.5 
mmHg. Reperfusion resulted in a further increase in the 
diastolic pressure which reached a peak 3 min after reper- 
fusion. At the end of reperfusion, recovered pressure was 
21.7% with respect o baseline value (Fig. 1). 
Administration of ergothioneine at 10 -5 (group 2) and 
10 -4  M (group 3) had no effect on the mechanical func- 
tion during 135 min of aerobic perfusion and failed to 
improve the mechanical function during ischaemia and 
reperfusion. After reperfusion, the developed and diastolic 
pressures were: 14.4 + 2.3 and 44.3 ___ 4.4 mmHg in group 
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Fig. 1. Effect of ergothioneine (E) on myocardial function. Mean data 
(+ S.E.M.) of the left ventricular (LV) pressures are reported. Ergoth- 
ioneine was delivered at 10 -5 M (n = 4) and 10 -4 M (n = 5) before 
ischaemia (during the aerobic period of 60 min) and during reperfusion. 
The other hearts received saline vehicle (n = 7). 
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Fig. 2. Effect of ergothioneine on the reperfusion-induced r lease of CK 
(A) and lactate (B). The values are given as mean 5: S.E.M. For other 
details, see the legend to Fig. 1. 
1; 10.3 +__ 2.9 and 49.8 +5.8 mmHg in group 2; 12.5 ± 2.3 
and 48.0 ___ 7.7 mmHg in group 3 (Fig. 1). No statistically 
significant differences were found among the groups. 
Further evidence of the lack of ergothioneine efficacy is 
provided by data on the release of CK and lactate shown in 
Figs. 2A and B. During aerobic perfusion, small amounts 
of CK (from 123.7 + 12.0 initially to 42.4 + 14.7 mU/min 
per g wet weight at the end of perfusion) and of lactate 
(from 1.89 + 0.16 to 2.10 _ 0.16 /xmol/min per g w.w.) 
were present in the coronary effluent, independent of the 
presence of ergothioneine. Fig. 2A shows that the release 
of CK progressively increased uring reperfusion and that 
there were no statistical differences among the three groups. 
The release of lactate, reported in Fig. 2B, reached a peak 
during the first minute of reperfusion and suddenly de- 
creased until it reached the baseline level, suggesting that 
reperfusion caused a washout of the lactate accumulated 
during ischaemia. The release of lactate from group 1, 2 
and 3 hearts was not significantly different. 
We investigated the effects of ergothioneine on the 
intracellular thiol pool and its ability to reduce oxidative 
stress upon reperfusion. The reductant action of ergoth- 
ioneine is thought o depend on an ergothioneine GSH 
redox couple which, in turn, could be of physiological 
relevance. Oxidative stress was measured as the myocar- 
dial content of GSH and GSSG, and of protein and non- 
protein thiol groups [17]. Table 1 shows that ergothioneine 
does not affect he myocardial content of GSH, NP-SH and 
P-SH after 60 min of aerobic perfusion. In addition, er- 
gothioneine failed to prevent he depletion of myocardial 
thiol groups and the accumulation of GSSG after is- 
chaemia nd reperfusion. 
Ergothioneine had no positive effect on energy 
metabolism evaluated as the content of high energy phos- 
phates and as the NAD/NADH ratio. As expected [28], 
for group 1 (control) after 30 min of reperfusion, the levels 
of nucleotide in the tissue were low compared to the 
aerobic values before ischaemia (P<0.001).  Ergoth- 
ioneine treatment (groups 2 and 3) failed to increase the 
myocardial content of nucleotides. Interestingly, atthe end 
of the reperfusion, the level of ATP was still reduced in all 
groups while the level of CP had recovered almost o the 
aerobic value (Table 2). This finding is supported by data 
in the literature which show a faster rate of restoration of 
CP than of ATP resynthesis during the early minutes of 
Table 1 
Myocardial content of GSH, GSSG, protein- and non-protein-thiol groups 
Group No. of expts. GSH GSSG NP-SH P-SH TOTAL-SH 
(nmol/mg prot.) (nmol/mg prot.) (nmol/mg prot.) (nmol/mg prot.) 
Aerobic control 6 11.61 + 0.42 0.175 ± 0.028 18.8 + 1.6 252.0 -I- 13.4 271.0 -I- 14.8 
Aerobic treatment-E 10-SM 4 12.01 5:0.51 0.163 5- 0.018 19.3 + 1.3 265.8 + 10.9 285.9 + 15.1 
Aerobic treatment-E 10 -4 M 4 11.35 + 0.80 0.192 ± 0.032 20.1 5- 0.9 249.5 -t- 12.4 290.1 + 18.2 
Group 1 7 9.58 5- 0.34 0.270 5- 0.033 a 13.9 + 0.7 b 214.0 + 11.9 b 237.9 + 12.3 
Group 2 4 8.31 + 0.31 a 0.250 5:0.043 a 10.6 5:1.2 a 211.2 ___ 16.6 b 221.8 5:18.0 b 
Group 3 5 8.56 5:1.41 b 0.196 5:0.040 a 11.4 5:2.5 b 173.8 5:18.6 a 185.1 -t- 21.1 a 
The values pertain to the end of the perfusion period. The data are expressed as mean + S.E.M. E = ergothioneine. 
a p < 0.01 vs. aerobic ontrol. 
b p < 0.05 vs. aerobic ontrol. 
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Table 2 
Effects of ergothioneine on myocardial metabolism 
177 
Group NO. of expts. CP Nucleotide ( / zmol /g  d.w.) 
( / . tmol/g d.w.) ATP ADP AMP Ad-Nucl NAD/NADH 
Aerobic control 6 46.0 _ 3.0 18.5 ± 1.35 3.7 + 0.4 0.98 + 0.25 23,2 + 2.1 23.6 + 1.0 
Aerobic treatment-E 10 -5 M 4 43.8 ± 4.1 20.1 ± 2.1 4.1 + 0.6 0.85 + 0.15 25,05 _ 2.85 24.0 ± 1.2 
Aerobic treatment-E 10 -4 M 4 49.7 ± 6.2 21.0 _+ 2.5 3.8 + 0.4 0.78 ± 0.31 25.58 +__ 3.21 25.9 _+ 1.6 
Group 1 7 34.3 ± 5.6 3.2 + 0.6 " 2.1 + 0.45 b 0.79 + 0.14 6.1 + 1.2 " 6.6 + 1.1 a 
Group 2 4 27.3 + 6.3 b 2.7 + 0.7 ~ 1.9 ± 0.2 b 1.10 + 0.31 5.7 + 1.2 a 12.1 + 4.8 b 
Group 3 5 31.3 ± 5.8 3.4 ± 0.6 a 2.6 ± 0.24 1.26 + 0.34 7.3 + 1.2 a 7.0 + 1.5 a 
The values pertain to the end of the perfusion period. The data are expressed as mean ___ S.E.M. E = ergothioneine, Ad-Nucl = adenine nucleotides. 
a p < 0.001 vs. aerobic ontrol. 
b p < 0.05 vs. aerobic ontrol. 
reperfusion [29]. Table 2 shows that the NAD/NADH 
ratio was unchanged by the administration of ergoth- 
ioneine. This ratio is an important index of aerobic 
metabolic work. Under aerobic onditions, when the Krebs 
cycle produces NADH and the mitochondrial respiratory 
chain produces ATP, the NAD/NADH ratio is elevated. 
On the other hand, ischaemia reduces this ratio [30,31]. 
4. Discussion 
The reported data indicate that, in our experimental 
model, the administration of ergothioneine failed to reduce 
damage caused by reperfusion following ischaemia. In our 
preliminary plan, we had chosen to administer ergoth- 
ioneine at a concentration f 10 -5 M which is an interme- 
diate dosage between that used by Arduini et al. [14] and 
the dosage used in our laboratory for other sulfhydryl 
molecules [17,32]. We also repeated the experiments with 
the higher concentration of 10 -4  M,  however a further 
increase of dosage was considered to be physiologically 
not relevant. 
Ergothioneine proved to be unable to improve restora- 
tion in aerobic metabolism and in high energy phosphate 
content as shown by a low value for the NAD/NADH 
ratio and reduced ATP and CP levels that persisted even 
after 30 min of reperfusion. Ergothioneine treatment nei- 
ther reduces the membrane damage (given the massive CK 
release during reperfusion) nor limits the mechanical dete- 
rioration observed under reperfusion. Finally, ergoth- 
ioneine did not affect the occurrence of reperfusion oxida- 
tive stress. It failed to overcome the decline of myocardial 
GSH and the accumulation of myocardial GSSG. It did not 
participate in the thiol/disulfide metabolism, proving to be 
unable to increase the aerobic myocardial levels of the 
thiol pool (determined as GSH, NP-SH and P-SH) and the 
available cellular reductant equivalents. Consequently, it 
cannot limit the drop in thiol group levels during reperfu- 
sion. 
Our findings are in contrast with data reported by 
Arduini et al. [14], showing that ergothioneine d livered to 
isolated rat hearts ignificantly reduced the reperfusion-in- 
duced release of LDH and CK. This discrepancy can be 
explained considering several differences in the experi- 
mental models. First, there is a species difference since we 
used rabbits instead of rats. Second, there is a difference in 
the perfusion methodology as we employed a non-recir- 
culating Langendorff preparation i stead of a recirculating 
perfusion. Third, the duration of ischaemia was substan- 
tially longer in our model: 45 min instead of 15 rain. The 
dosage used for ergothioneine was nevertheless the same. 
Unfortunately, it is not possible to compare the damage 
degree induced by these different models as mechanical 
function and amount of CK release were not reported in 
the paper of Arduini et al. However, their experimental 
protocol was designed to test the ergothioneine effect on 
myoglobin rather than to systematically evaluate the 
metabolic interaction of this agent with the myocardial 
thiol pool, and to assess its metabolical implications. 
It is difficult to explain the negative findings about the 
antioxidant effect of ergothioneine. These are not due to an 
inadequacy of our experimental model as we tested in the 
same experimental setting the antioxidant capacity of N- 
acetylcysteine and dimercaptopropanol, two sulfhydryl 
agents able to significantly improve all the measurements 
considered in this study [17,32]. The inefficacy of ergoth- 
ioneine is most likely due to the poor biological availabil- 
ity of its thiol group which, in aqueous conditions, is 
predominantly present as the thione rather than as the thiol 
form [2] (Fig. 3). 
An increase of the dosage used could possibly over- 
come the ergothioneine poor thiol availability, since its 
reductant activity is reported in cardiac tissue only when 
H H H H 
C- -N  C- -N~ 
C__N//~ 
% 
HCH "<-- H H 
I +/CH~ I + .CH3 
HC--N --ell 3 HC--N .~----CH 3 
[ _ ~CH~ t _ \CH3 
COO COO 
Thloll¢ form Thionic form 
Fig. 3. Tautomeric forms of ergothioneine in aqueous olution. 
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used at 2 mM concentration [33]. Further experiments will 
need to be carried out in order to study the bioavailabil ity 
of the ergothioneine thiol group under physiological and 
pathological conditions. 
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